<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03966625</url>
  </required_header>
  <id_info>
    <org_study_id>DSBUS</org_study_id>
    <nct_id>NCT03966625</nct_id>
  </id_info>
  <brief_title>Serological Identification of Celiac Disease in Kids</brief_title>
  <acronym>SICK</acronym>
  <official_title>Serological Identification of Celiac Disease in Kids (Swedish: Screening för Celiaki på Barnmottagning)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to examine the feasibility of incorporating serological celiac disease
      (CD) screening into general pediatric outpatient clinics in Sweden and through structured
      monitoring examine the effects of diagnosing and treating screening-detected CD.

      Screening will be tailored to general pediatric outpatient clinics in the Gothenburg
      metropolitan area with the goal to screen 1000 children over four months. Screening for CD
      will be carried out by measuring tissue transglutaminase autoantibodies (TGA) in blood.
      Children who are persistently TGA positive will be enrolled into a 6-12-month follow-up
      protocol responsible for diagnosing CD, installation of gluten-free diet and to assess their
      short-term impact upon the child's wellbeing. Other components to assess include (I) the
      feasibility to incorporate CD screening into busy pediatric practices; (II) parental/child
      interest in, and satisfaction with, participating in a CD screening program and (III)
      identifying key considerations for a possible scaled-up, broad-based, CD screening.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants diagnosed with celiac disease</measure>
    <time_frame>Assessed after 6-12 months of follow-up</time_frame>
    <description>Celiac disease diagnosed according to European pediatric (ESPGHAN) guidelines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants identified with celiac disease autoimmunity</measure>
    <time_frame>Assessed after performed two tests of TTG (apprx. 1-2 months after enrollment)</time_frame>
    <description>Celiac disease autoimmunity defined by having two consecutive positive tests for tissue transglutaminase (TTG) autoantibodies</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Celiac Disease in Children</condition>
  <condition>Pediatric Disorder</condition>
  <condition>Health, Subjective</condition>
  <condition>Growth Delay</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>tissue transglutaminase autoantibodies</intervention_name>
    <description>celiac disease-specific autoantibodies</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at pediatric outpatient clinics in Gothenburg metro area
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 2-17 years old

          -  Patient at pediatric outpatient clinics in Gothenburg metro area

          -  Parental and adolescent consent to screening

        Exclusion Criteria for serological screening:

          -  Established celiac disease diagnosis

          -  Type 1 diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karl Mårild, PhD</last_name>
    <phone>00463431000</phone>
    <email>karl_marild@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>BUMM Hisingen</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Mårild</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 25, 2019</study_first_submitted>
  <study_first_submitted_qc>May 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>November 27, 2019</last_update_submitted>
  <last_update_submitted_qc>November 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Karl Mårild</investigator_full_name>
    <investigator_title>Pediatrican, associate professor</investigator_title>
  </responsible_party>
  <keyword>screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoantibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be shared in accordance with the ethical approval of this study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

